Population Pharmacokinetics and Exposure–Response Relationships of Etrolizumab in Patients with Moderately-to-Severely Active Crohn’s Disease

New publication, in collaboration with Genentech, on etrolizumab for treatment of Crohn’s disease (CD), a chronic inflammatory bowel disease (IBD) that can cause severe complications, significantly impacting patient quality of life. To develop effective biologic treatments such as etrolizumab, it’s crucial to gain a clear understanding of its pharmacokinetics (PK) and its relationship to patient response. This work provides a strong showcase for how strategic submission analyses and efficient pharmacometrics can significantly cut reporting timelines.

This analysis provides key insights into the drug’s behavior using an efficient modeling strategy:

• Time-varying clearance – the analysis confirmed that, as with other monoclonal antibody therapies (mAbs) in IBD, etrolizumab clearance decreases over the course of treatment, likely due to a reduction in disease activity.
• The population PK analysis (based on 2312 patients with CD or ulcerative colitis, assigned to active Etrolizumab) estimated an eventual 22% reduction in CL (albeit with high between-subject variability).
• Addressing confounding: to avoid confounding between disease improvement and drug exposure in the Exposure-Response (ER) analysis, the initial Week 4 “trough” concentration was used as the key independent exposure metric.
• The subsequent decrease in clearance did not affect exposure during the first dosing interval.
• Other confounding covariates were also accounted for in the ER analyses.
• Modeling efficiency – by using logistic regression information in landmark analyses of various outcomes, the team was able to shorten the analysis and reporting phase significantly.